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Abstract
Background: Pseudoexfoliation syndrome is a major risk factor for glaucoma in many populations
throughout the world. Using a U.S. clinic-based case control sample with broad ethnic diversity, we
show that three common SNPs in LOXL1 previously associated with pseudoexfoliation in Nordic
populations are significantly associated with pseudoexfoliation syndrome and pseudoexfoliation
glaucoma.
Methods: Three LOXL1 SNPs were genotyped in a patient sample (206 pseudoexfoliation, 331
primary open angle glaucoma, and 88 controls) from the Glaucoma Consultation Service at the
Massachusetts Eye and Ear Infirmary. The SNPs were evaluation for association with
pseudeoexfoliation syndrome, pseudoexfoliation glaucoma, and primary open angle glaucoma.
Results: The strongest association was found for the G allele of marker rs3825942 (G153D) with
a frequency of 99% in pseudoexfoliation patients (with and without glaucoma) compared with 79%
in controls (p = 1.6 × 10-15; OR = 20.93, 95%CI: 8.06, 54.39). The homozygous GG genotype is also
associated with pseudoexfoliation when compared to controls (p = 1.2 × 10-12; OR = 23.57, 95%CI:
7.95, 69.85). None of the SNPs were significantly associated with primary open angle glaucoma.
Conclusion: The pseudoexfoliation syndrome is a common cause of glaucoma. These results
indicate that the G153D LOXL1 variant is significantly associated with an increased risk of
pseudoexfoliation and pseudoexfoliation glaucoma in an ethnically diverse patient population from
the Northeastern United States. Given the high prevalence of pseudooexfoliation in this geographic
region, these results also indicate that the G153D LOXL1 variant is a significant risk factor for
adult-onset glaucoma in this clinic based population.
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Background
Glaucoma is one of the leading causes of blindness world-
wide and results in an irreversible degeneration of the
optic nerve that is usually associated with a high intraoc-
ular pressure. The disease is clinically and genetically het-
erogeneous with early onset forms exhibiting mendelian
inheritance while the common late onset forms have a
more complex genetic architecture. Several genes have
been associated with the mendelian forms of early-onset
glaucoma: defects in the myocilin gene (GLC1A) prima-
rily cause elevated pressure [1,2], the optineurin gene
(GLC1E), appears to contribute to disease in familial low
tension glaucoma [3-5]; and the WDR36 gene (GLC1G)
may be a modifier gene that influences the severity of the
glaucoma phenotype [6,7]. Seven other glaucoma gene
loci (GLC1B, GLC1C, GLC1D, GLC1F, GLC1H, GLC1J,
GLC1K) have been identified using large affected pedi-
grees and Mendelian linkage approaches [8-15].
Primary open angle glaucoma (POAG) and glaucoma
associated with pseudoexfoliation (PXF, also called exfo-
liation) are the most common types of adult onset glau-
coma. A positive family history is a major risk factor for
these conditions, which suggests that specific gene defects
are likely to contribute [16-20]; however, the genetic con-
tributions to these disorders are complex and are likely to
involve multiple genetic factors and possibly the influence
of environmental exposures. Genome studies have been
completed for POAG but as yet genes conferring signifi-
cant susceptibility have not been identified [18,21-23].
Pseudoexfoliation syndrome results in the deposition of
microfibrillar material throughout the eye. In over 50% of
cases this condition is associated with glaucoma charac-
terized by elevated intraocular pressure and optic nerve
degeneration [24]. The nature of the deposited microfi-
brillar material is not known, and in addition to the eye it
has also been identified in systemic tissues including renal
vasculature, skin and liver [25]. Unlike other forms of
glaucoma, systemic conditions have also been associated
with pseudoexfoliation including abdominal aortic aneu-
rysm [26], and elevated levels of serum homocysteine
[27].
Familial aggregation studies have suggested a significant
genetic contribution to pseudoexfoliation glaucoma
[16,17,19], and one genome scan has recently been pub-
lished [28]. However, the late age of onset makes genetic
approaches using multigenerational families difficult.
Recently, a whole genome association study using a col-
lection of cases and controls from Iceland and a second
population from Sweden identified a strong association
between single nucleotide polymorphisms (SNPs) in the
LOXL1 gene in patients with pseudoexfoliation [29].
Three SNPs were found to be associated with the disease:
two nonsynonomous SNPs located within exon 1:
rs1048661 (R141L) and rs3825942 (G153D) and
rs2165241 located in the first intron of the gene. All three
of these SNPs were in significant linkage disequilibrium
(LD) in the studied population. This study reported odd
ratios of 2.46 for allele G of rs1048661 and 20.10 for
allele G of rs3825942 and 3.62 for allele T of rs2165241.
Taken together these SNPs account for 99% of pseudoex-
foliation cases in this homogenous population.
Independent replication studies are required to accurately
assess the contribution of the associated alleles to com-
plex disease, and in this case replication is especially
important because the studied Nordic population has a
limited gene pool and a very high prevalence of pseudoex-
foliation [19,30]. To determine if the results from the Nor-
dic study are generalizable to a heterogeneous population
from the North eastern United States, we used an existing
sample (206 PXF, 331 POAG, and 88 controls) from the
Glaucoma Consultation Service at the Massachusetts Eye
and Ear Infirmary to provide independent estimates of the
association of LOXL1 SNPs with the pseudoexfoliation
syndrome and pseudoexfoliation glaucoma.
Methods
Patient population
206 PXF patients, 331 POAG patients, and 88 control
individuals were identified from the Glaucoma Consulta-
tion Service at the Massachusetts Eye and Ear Infirmary for
this study. All patients and controls were recruited after
informed consent, and the study was approved by the
Massachusetts Eye and Ear Infirmary Institutional Review
Board. For this patient population, glaucoma was defined
as elevation of intraocular pressure and optic nerve dis-
ease as previously described [18]. Patients with PXF were
identified by the presence of the characteristic fibrillar
material present in the ocular anterior segment. Patients
with iris transillumination defects without the presence of
the fibrillar material were not were not identified as pseu-
doexfoliation patients, POAG patients or controls. Con-
trols did not have fibrillar material, iris changes or
evidence of glaucoma. Of the 206 patients with pseudoex-
foliation, 146 also had glaucoma. The POAG patients had
elevated intraocular pressure and optic nerve changes con-
sistent with glaucoma, but did not have any evidence of
psesudoexfoliation. The average age of the POAG patients
and the PXF patients was 75. Because of the age-depend-
ence of the pseudoexfoliation syndrome, only controls
older than age 60 were used for this analysis with an aver-
age age of 72. The patients and controls were primarily
Caucasian of European ancestry but the studied popula-
tion also included African-Americans (6% of PXF, 22% of
POAG and 6% of controls). 58% of the patients were
female with 42% male, while 57% of the controls were
female and 43% were male.BMC Medical Genetics 2008, 9:5 http://www.biomedcentral.com/1471-2350/9/5
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Genotyping
Genotyping for rs2165241 and rs3825942 was performed
for all samples using ABI TaqMan assays (assay by
demand) performed according to the manufacturers
instructions. rs1048661 was genotyped using direct
sequencing, and the genotypes for all three SNPs were
confirmed by direct genomic sequencing of a random
group of samples (Table 1). For sequencing, products
from PCR amplification were purified and sequenced
using ABI BIG DYE chemistries and an automated ABI
3100 genetic analyzer. Sequence data was analyzed using
the Vector NTI software package. The primer sequences
and PCR conditions for LOXL1 sequencing are listed in
Table 1. The observed genotypes of all 3 SNPs did not
deviate from Hardy-Weinberg Equilibrium.
Statistical analysis
The observed genotype frequencies in the patients and
controls were tested for Hardy-Weinberg equilibrium
(HWE) and the difference between the observed and
expected frequencies was tested for significance using chi-
square test. Association analyses were performed using
SAS statistical software (version 9.1.3; SAS Institute, Cary,
NC). Fisher's exact test was used to compare allele or gen-
otype frequencies of PXF or POAG patients with controls.
The confidence intervals (CIs) for ORs were calculated by
the logit method. Haplotype frequencies were estimated
and tested using WHAP [31]. Conditional analysis based
on haplotypes was performed using WHAP [31]. The LD
analysis was performed using Haploview [32]. Multiple
testing was adjusted using the Bonferroni correction.
Results
LOXL1 SNP association studies
Three common LOXL1 SNPs (rs1048661, rs3825942, and
rs2165241) were used for these studies. Genotypes were
determined for all three SNPs for the PXF patients, POAG
patients and controls. The G allele of rs3825942 was
found in a significantly higher frequency in pseudoexfo-
liation patients (with and without glaucoma) than in
POAG patients or in control samples (99% in PXF, 77%
in POAG and 79% in controls, p = 1.6 × 10-15 (Table 2).
The GG genotype was also significantly associated with
pseudoexfoliation (98%; p = 1.2 × 10-12; OR = 23.57,
95%CI: 7.95, 69.85) compared with POAG patients
(59%) and controls (68%). The T allele of the intronic
SNP, rs2165241 was also significantly more frequent in
pseudoexfoliation patients than in POAG patients or con-
trols (p = 1.2 × 10-11) and the TT genotype was also signif-
icantly associated with the pseudoexfoliation condition
(p = 5.0 × 10-10; OR = 4.14, 95%CI: 2.32, 7.39). In this
population we did not find a highly significant associa-
tion between pseudoexfoliation and the other nonsynon-
Table 1: Primer sequences and PCR conditions for LOXL1 sequencing
Exon Primer Sequence MgCl2 (mM) Annealing Temperature (°C) Amplicon (bp)
1A F: TCCCAGCCTGTTGCTTATTC 1.5 55 326
R: AGGCCTGGTGGACAGAGAG
1B F: AAGCAAGGAGCCTTCCTGTC 1.5 55 260
R: GTACACCTGCCCGTTGTTCT
1C* F: GCAGGTGTACAGCTTGCTCA 1.5 55 464
R: ACACGAAACCCTGGTCGTAG
1D F: CTCCTACCCGCAGCAGTTC 1.5 55 227
R: GGTACTCGGGCAGCTCTTC
1E F: CGACCAGGGTTTCGTGTACT 1.5 55 280
R: AGGGTAGGCCTGCTCGAAG
1F F: AGCAGGCCTACCCTGACC 1.5 55 340
R: GCCTCCAGGAAGTTCTAAGGA
2 F: GGAGGTCTCTGGGCATTAGC 1.5 58 354
R: TCACTGATGAAACGGTCAGG
3 F: TCTTCAGGGACAAGGAGTGG 1.5 58 357
R: AGTGCTCATGGTGGGAGG
4 F: CAGGGAAGACTAGGCCCTCT 1.5 58 324
R: CTGTGAGCAGAGCTGAGTGG
5 F: GAAACAAGCAGCATCACAGC 1.5 58 220
R: GGCTGAAGCTTCTTTCAGGA
6 F: TCTGGTGAGCAGTTGAGGTG 1.5 58 202
R: GGTGGGCAAACTCTTACTGG
7 F: CCCTCATTGACCCACTGTCT 1.5 58 356
R: GCATGCAGAGCCACAGAGTA
Note.-F: forward; R: reverse.
*The SNP rs1048661 is located in exon 1 and was analyzed in this amplicon.BMC Medical Genetics 2008, 9:5 http://www.biomedcentral.com/1471-2350/9/5
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ymous SNP (rs1048661, R141L) with significant
association in the Nordic population.
For this case control cohort, the attributable risk of the GG
genotype for rs3825942 is approximately 99% (Table 2).
Although our sample is primarily Caucasian patients of
European ancestry the studied population also included
African-Americans (6% of PXF, 22% of POAG and 6% of
controls). The rs3825942 GG genotype was more frequent
in African Americans with PXF in the sample (100% PXF,
40% POAG, 20% controls; p = 0.0007, Fisher's exact test),
compared with African American POAG patients and con-
trols although the sample size was too small to reach
genome-wide statistical significance. The association with
pseudoexfoliation was not different between patients with
only the pseudoexofoliation syndrome compared with
patients with pseudoexfoliation glaucoma, arguing that
the LOXL1 protein participates in the syndrome and in
the associated glaucoma. Interestingly, POAG is not asso-
ciated with these LOXL1 SNPs (Table 2), which suggests
that a different set of genetic factors contributes to this
condition.
Haplotype analyses and linkage disequilibrium
To determine if the rs3825942 association effect is inde-
pendent of the other two SNPs, we investigated the haplo-
type associations for the patient sample. Haplotype
frequencies were estimated and tested using WHAP [31].
The most common haplotype (TGG) consisting of all 3
risk alleles had significantly higher frequency in PXF
patients than in controls (p = 2.8 × 10-11; OR = 3.66,
95%CI: 2.53, 5.30; Table 3). The association of rs3825942
with PXF was still significant after controlling for the effect
of the other two SNPs (p = 0.002). This suggests that the
effect of rs3825942 on PXF is independent of rs1048661
and rs2165241. Conversely, rs1048661 and rs2165241
were no longer associated with PXF after controlling for
the other SNPs (p = 0.98 and 0.43 respectively). The two
coding SNPs (rs1048661 and rs3825942) were reported
to be in strong LD (D' = 1.0) in the Nordic population
[29]. However, our analysis showed that they were in less
LD in our heterogenous populations, especially in PXF
patients (D' = 0.09, r2 = 0).
LOXL1 sequence analyses
To determine if other common DNA sequence variants in
LOXL1 contribute to the PXF phenotype, we sequenced all
7 exons of the LOXL1 gene and the flanking intronic
regions in 7 randomly selected pseudoexfoliation
patients. The genotypes for SNPs rs3825942, rs1048661,
and rs2165241 were confirmed in this sample, however,
Table 2: Distribution of LOXL1 sequence variants in PXF patients, POAG patients and Controls
Genotype Frequency (%) Allele Frequency (%)
rs1048661 (R141L) NT TT G G G P_value T G P_value OR G/T (95%CI)
PXF 199 6 (3.0) 56 (28.1) 137 (68.9) 0.011 68 (17.1) 330 (82.9) 0.005 1.90 (1.23, 2.93)
PXF (Glaucoma) 141 2 (1.4) 41 (29.1) 98 (69.5) 0.0028 45 (16.0) 237 (84.0) 0.0031 2.06 (1.29, 3.30)
PXF (No Glaucoma) 58 4 (6.9) 15 (25.9) 39 (67.2) 0.36 23 (19.8) 93 (80.2) 0.12 1.58 (0.89, 2.80)
POAG 304 29 (9.5) 110 (36.2) 165 (54.3) 0.84 168 (27.6) 440 (72.4) 0.92 1.02 (0.70, 1.51)
Controls 80 9 (11.3) 27 (33.7) 44 (55.0) 45 (28.1) 115 (71.9)
rs3825942 (G153D) NA AA GG G P_value A G P_value OR G/A (95%CI)
PXF 206 1 (0.5) 3 (1.5) 202 (98.0) 1.2 × 10-12 5 (1.2) 407 (98.8) 1.6 × 10-15 20.93 (8.06,54.39)
PXF (Glaucoma) 146 0 (0.0) 3 (2.1) 143 (97.9) 7.3 × 10-11 3 (1.0) 298 (99.0) 1.3 × 10-13 24.77 (7.50, 81.83)
PXF (No Glaucoma) 60 1 (1.7) 0 (0.0) 59 (98.3) 1.4 × 10-6 2 (1.7) 118 (98.3) 2.7 × 10-7 15.17 (3.58, 64.34)
POAG 325 17 (5.2) 115 (35.4) 193 (59.4) 0.044 149 (22.9) 501 (77.1) 0.54 0.86 (0.57, 1.30)
Controls 88 8 (9.1) 20 (22.7) 60 (68.2) 36 (20.5) 140 (79.5)
rs2165241 (intron) NC CC T T T P_value C T P_value OR T/C (95%CI)
PXF 200 12 (6.0) 72 (36.0) 116 (58.0) 5.0 × 10-10 96 (24.0) 304 (76.0) 1.2 × 10-11 3.77 (2.56, 5.55)
PXF (Glaucoma) 143 7 (4.9) 54 (37.8) 82 (57.3) 2.1 × 10-9 68 (23.8) 218 (76.2) 1.5 × 10-10 3.82 (2.53,5.78)
PXF (No Glaucoma) 57 5 (8.8) 18 (31.6) 34 (59.7) 4.0 × 10-5 28 (24.6) 86 (75.4) 1.0 × 10-6 3.66 (2.16, 6.21)
POAG 323 116 (35.9) 148 (45.8) 59 (18.3) 0.40 380 (58.8) 266 (41.2) 0.33 0.83 (0.59, 1.18)
Controls 80 27 (33.7) 33 (41.3) 20 (25.0) 87 (54.4) 73 (45.6)
P values and OR are calculated when compared to controls. Association analyses were performed using SAS statistical software (version 9.1.3; SAS 
Institute, Cary, NC). Fisher's exact test was used to compare allele or genotype frequencies of PXF or POAG patients with controls. The 
confidence intervals (CIs) for ORs were calculated by the logit method. Hardy-Weinberg equilibrium was tested by chi-square test.BMC Medical Genetics 2008, 9:5 http://www.biomedcentral.com/1471-2350/9/5
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we did not find other DNA sequence variants that were
significantly associated with the condition.
Discussion
The results of this study provide strong evidence for an
association between DNA sequence variants in LOXL1
and pseudoexfoliation in a clinic-based population from
the Northeastern United States. In this patient population
the strongest association is found for a nonsysnonomous
SNP, G152D, which is also one of the SNPs that demon-
strated the strongest association in the Nordic population.
Interestingly, the second nonsynonomous SNP showing
significance in the Nordic population, R141L, is not sig-
nificantly associated with pseduoexfoliation in our ethni-
cally diverse clinic-based sample. This result probably
reflects a difference in patterns of linkage disequilibrium
between our ethnically heterogeneous patient population
and the relatively homogeneous Nordic population. Very
recently, associations between these LOXL1 SNPs and
pseudoexfoliation patients in Australia [33] and the Mid-
western US [34] have been reported. The results from Aus-
tralia support an association that is not as strong as that
seen in the Midwestern US or our study where the popu-
lation attributable risk is near 90%. The Australian popu-
lation has a nine-fold lower lifetime incidence of
pseudoexfoliation compared to the Nordic populations
and yet has similar distributions of LOXL1 genotypes
between cases and controls. These results suggest that
additional factors may influence the development of the
pseudoexfoliation phenotype.
Loxl1 is one member of a family of proteins that catalyze
the polymerization of tropoelastin to form the mature
elastin polymer [35]. The protein also participates in elas-
tin homeostasis and renewal, and is involved in spatially
organizing elastogenesis at sites of elastin deposition. This
function requires binding of LOXL1 to the elastin scaffold
that is formed from fibrillin-containg microfibrils [36]. In
a LOXL1 mouse knock-out abnormalities were detected in
the skin and the aorta, two tissues reminiscent of reported
findings in patients with psedueoxfoliation syndrome
[35]. The ocular elastic tissues have not been completely
characterized in the LOXL1 knock-out, and further inves-
tigations are ongoing. In pseudoexfoliation patients
abnormal fibrillar material accumulates in the eye and in
systemic tissues, and abnormal elastin formation has also
been described in some tissues including the optic nerve
[37,38]. Further characterization of tissues expected to be
involved in glaucoma in the LOXL1 knock-out is currently
underway.
The DNA sequence variants in LOXL1 that are associated
with pseudoexfoliation are all located in the noncon-
served N-terminal sequence that may have a regulatory
function [35,36]. This portion of the protein may play a
role in directing the LOXL1 protein to sites of elastogene-
sis, but is unlikely to affect the catalytic activity of the pro-
tein. Although the DNA sequence variant most
significantly associated with the phenotype is a nonsyn-
onymous SNP (G153D), the biological effect of this mis-
sense change has not been determined. It is possible that
the variants associated with pseudoexfoliation are in link-
age disequilibrium with other DNA sequence changes that
affect gene expression, and further studies to investigate
the level of LOXL1 mRNA and protein in ocular tissues
from patients with pseudoexfoliation would be necessary
to determine if a reduction in LOXL1 mRNA or protein is
responsible for the condition. The genomic location of
the LOXL1 gene overlaps in a head to tail fashion with a
novel gene coding for an untranslated mRNA (FLJ31814),
and all of the sequence variants known to be associated
with pseudoexfoliation are located in the overlapped seg-
Table 3: Haplotype analysis of rs1048661, rs3825942 and rs2165241 in PXF patients and Controls
Estimated haplotype frequency (%)
Haplotype PXF Controls Combined P_value OR (95%CI)
GGT 75.3 45.4 66.3 2.8 × 10-11 3.66 (2.53, 5.30)
TGC 16.3 26.3 19.3 0.0057 0.54 (0.35, 0.83)
GAC 1.3 19.7 6.8 1.9 × 10-12 0.05 (0.02, 0.13)
GGC 6.6 7.2 6.8 0.78 0.88 (0.44, 1.74)
TGT 0.6 0.7 0.6 0.78 0.85 (0.08, 9.45)
GAT 0.0 0.6 0.2 0.11 -
TAC 0.0 0.0 0.0 1.00 -
TAT 0.0 0.0 0.0 1.00 -
Total 100.0 100.0 100.0 1.8 × 10-11*-
*This P value was obtained from the omnibus test using WHAP,31 while the other P values were obtained from the haplotype-specific test. OR was 
calculated for each individual haplotype compared to all the other haplotypes. 'GGT' is the combination of 'at risk' alleles at all three SNPs.BMC Medical Genetics 2008, 9:5 http://www.biomedcentral.com/1471-2350/9/5
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ment. This untranslated mRNA has reported ocular
expression, although its function is completely unknown
[39].
Conclusion
This study demonstrates that DNA sequence variants in
LOXL1 are strongly associated with pseudoexfoliation
and pseudoexfoliation glaucoma in a heterogeneous
clinic-based population with broad ethnic diversity. The
strength of the association in this heterogeneous popula-
tion is similar to that observed for pseudoexfoliation
patients from the relatively homogenous Nordic popula-
tion confirming the generalizability of this result. The var-
iants associated with the disease are common and thus are
also prevalent in the unaffected control sample. Given the
complex inheritance of this condition it is highly likely
that additional genetic factors and/or environmental
exposures could influence the development of the disease.
Other members of the LOX family as well as other pro-
teins that contribute to the maintenance of elastic fibers
and composition of the extracellular matrix are excellent
candidates for additional genetic factors that could con-
tribute to this common blinding disease.
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